Medicare Enrolled
Dr. Lane Ziegler, DO
Hematology · Largo, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Ziegler from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ziegler? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Ziegler
Dr. Lane Ziegler is a hematology in Largo, FL, with 20 years in practice. Based on federal Medicare data, Dr. Ziegler performed 95,433 Medicare services across 2,208 unique beneficiaries.
Between the years covered by Open Payments, Dr. Ziegler received a total of $4,891 from 62 pharmaceutical and/or device companies across 258 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ziegler is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 45% volume in FL$ $4,891 industry payments
Medicare Practice Summary
Medicare Utilization ↗95,433
Medicare services
Top 45% in FL for hematology
2,208
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~4,772 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) | 31,500 | $0 | $5 |
| Iron infusion (Feraheme) | 17,850 | $0 | $4 |
| Pembrolizumab injection (Keytruda) | 15,400 | $43 | $137 |
| Anti-nausea injection (aprepitant) | 8,060 | $1 | $5 |
| Epoetin alfa injection (Procrit) for anemia | 8,010 | $6 | $23 |
| Denosumab injection (Prolia/Xgeva) | 3,240 | $18 | $51 |
| Dexamethasone injection (steroid) | 1,820 | $0 | $3 |
| Complete blood count (CBC) with differential | 1,662 | $8 | $29 |
| Blood draw (venipuncture) | 1,493 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,270 | $1 | $28 |
| Office visit, established patient (20-29 min) | 1,129 | $67 | $239 |
| Anti-nausea injection (ondansetron/Zofran) | 628 | $0 | $9 |
| Drug injection, under skin or into muscle | 570 | $10 | $69 |
| Administration of chemotherapy into vein, 1 hour or less | 398 | $96 | $378 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 357 | $21 | $84 |
| Injection, carboplatin, 50 mg | 287 | $2 | $41 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 245 | $46 | $189 |
| Injection of additional new drug or substance into vein | 195 | $11 | $61 |
| Office visit, established patient (30-39 min) | 164 | $98 | $339 |
| Injection, diphenhydramine hcl, up to 50 mg | 145 | $1 | $3 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 141 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 121 | $15 | $56 |
| Administration of additional new drug or substance into vein, 1 hour or less | 97 | $49 | $178 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 94 | $24 | $89 |
| Administration of additional new drug or substance into vein using push technique | 81 | $42 | $170 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 80 | $134 | $562 |
| Automated urinalysis | 46 | $2 | $8 |
| Administration of chemotherapy into vein, each additional hour | 46 | $22 | $79 |
| New patient office visit (45-59 min) | 46 | $125 | $453 |
| Infusion, normal saline solution , 1000 cc | 46 | $2 | $7 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 38 | $17 | $59 |
| Hospital follow-up visit, moderate complexity | 33 | $63 | $197 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 30 | $3 | $11 |
| Injection of drug or substance into vein | 29 | $27 | $156 |
| Initial hospital admission, high complexity | 25 | $135 | $556 |
| Red blood count, automated test | 23 | $4 | $10 |
| Drawing of blood for a medical problem | 23 | $67 | $277 |
| Hospital follow-up visit, low complexity | 11 | $40 | $109 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
19.5% high complexity
75.3% medium
5.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,891
Total received (2018-2024)
Avg $699/year across 7 years
Bottom 41% in FL for hematology
62
Companies
258
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,885 (99.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$6 (0.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,112
2023$1,017
2022$924
2021$325
2020$198
2019$500
2018$814
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$833
E.R. Squibb & Sons, L.L.C.
$273
Gilead Sciences, Inc.
$245
Seagen Inc.
$237
PFIZER INC.
$208
Celgene Corporation
$179
Lilly USA, LLC
$172
Merck Sharp & Dohme LLC
$165
Astellas Pharma US Inc
$160
Eisai Inc.
$131
CSL Behring
$123
Incyte Corporation
$119
Amgen Inc.
$114
Ethicon US, LLC
$113
Takeda Pharmaceuticals U.S.A., Inc.
$113
Janssen Biotech, Inc.
$92
ABBVIE INC.
$86
Exelixis Inc.
$85
Merck Sharp & Dohme Corporation
$77
Kite Pharma, Inc.
$75
ARRAY BIOPHARMA INC
$72
Daiichi Sankyo Inc.
$70
Genentech USA, Inc.
$67
AVEO Pharmaceuticals, Inc.
$58
Regeneron Healthcare Solutions, Inc.
$57
TAIHO ONCOLOGY, INC.
$55
AstraZeneca Pharmaceuticals LP
$54
Bayer HealthCare Pharmaceuticals Inc.
$47
PharmaEssentia USA Corporation
$46
GENZYME CORPORATION
$45
EMD Serono, Inc.
$45
GlaxoSmithKline, LLC.
$42
TESARO, Inc.
$41
AbbVie, Inc.
$37
Deciphera Pharmaceuticals Inc.
$33
INSYS Therapeutics Inc
$32
Tempus AI, Inc
$29
Novocure Inc.
$28
Ipsen Biopharmaceuticals, Inc
$24
SANOFI-AVENTIS U.S. LLC
$24
Pharmacosmos Therapeutics Inc.
$24
ADC Therapeutics America, Inc.
$23
BeiGene USA, Inc.
$22
SERVIER PHARMACEUTICALS LLC
$22
Pharmacyclics LLC, an AbbVie Company
$22
Taiho Oncology, Inc.
$21
Myriad Genetic Laboratories, Inc.
$21
NOVARTIS PHARMACEUTICALS CORPORATION
$21
Alexion Pharmaceuticals, Inc.
$19
MorphoSys, US Inc.
$17
PUMA BIOTECHNOLOGY, INC.
$17
Janssen Pharmaceuticals, Inc
$17
Myovant Sciences Inc.
$16
Karyopharm Therapeutics Inc.
$16
Sobi, Inc
$16
Array BioPharma Inc.
$15
MEDIVATION FIELD SOLUTIONS LLC
$15
JAZZ PHARMACEUTICALS INC.
$15
Helsinn Therapeutics (U.S.), Inc.
$14
GE HEALTHCARE
$14
Puma Biotechnology, Inc.
$13
Rigel Pharmaceuticals, Inc.
$6
Top 3 companies account for 27.6% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AFINITOR · AKYNZEO · ALUNBRIG · Afstyla · Avastin · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · Braftovi · CABOMETYX · CALQUENCE · CERTUS 140 MICROWAVE ABLATION SYSTEM · COSELA · CYRAMZA · Cabometyx · Creon · DARZALEX · DOPTELET · ELIQUIS · EXKIVITY · Enhertu · Erleada · FOTIVDA · Fabhalta · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INFLECTRA · INLYTA · Idelvion · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUTATHERA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MYLOTARG · MYRISK · NERLYNX · NINLARO · Nerlynx · Nplate · Nubeqa · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Optune · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · Padcev · Pomalyst · QINLOCK · REBLOZYL · Revlimid · Rezlidhia · SANDOSTATIN · SOMATULINE DEPOT · SUTENT · SYNDROS · Stivarga · TASIGNA · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tibsovo · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · Venclexta · XALKORI · XARELTO · XGEVA · XPOVIO · XT CDX · XTANDI · Xtandi · Yescarta · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $5 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
37
Per 100K population
3.9
County median income
$70,293
Nearest hospital
HCA FLORIDA NORTHSIDE HOSPITAL
3.1 mi
3.1 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Ziegler is a mixed practice specialist, with moderate Medicare volume, and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Ziegler experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Ziegler performed 31,500 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ziegler receive payments from pharmaceutical companies?
Yes. Dr. Ziegler received a total of $4,891 from 62 companies across 258 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ziegler's costs compare to other hematologys in Largo?
Dr. Ziegler's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ziegler) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Largo
Browse hematologys in Largo ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology